

Figure S1




Figure S1: Shifts in circulating leukocyte composition and correlations with SARS-CoV2 titers in critical COVID-19. **a)** Average number of cells remaining after QC per donor per timepoint per disease severity status. **b)** Pearson correlation between electronic health record (EHR) and scRNA-seq derived blood counts for lymphocytes (left) and monocytes (right). Each datapoint is colored by disease severity status. **c)** UMAP projection of PBMCs colored by experimental run. **d)** Boxplots (showing median, 25th and 75th percentile) of the percentages of T4, Tgd, NK, cDC, pDC, Progen cells (y-axis) by COVID-19 status and severity level on day of hospital admission (D0). Each dot represents the percentage of a specific cell type per donor. Shown statistical comparisons are between cells from all C19+ critical donors (including the anti-IFN- α 2 autoantibody donors) and healthy controls (HC), C19- donors or combined C19+ Moderate-Severe donors. **e)** Boxplots of the percentages of T4, Tgd, NK, cDC, pDC, Progen cells (y-axis) in COVID-19 patients over day 0, 4, 7 and 14 since hospitalization (D0, D4, D7, D14). **f)** Boxplots of the percentages of T4, T8, Tgd, NK, B, PB, cM, ncM, cDC, pDC, Progen cells (y-axis) by COVID-19 status and severity level on day since first symptoms. **g)** Scatterplot of SARS-CoV2 viral titer as measured by qRT-PCR in tracheal aspirates (inverse dCT, x-axis) and days since hospitalization (left) or days since first symptoms (rights) (R = Pearson correlation). **h)** Scatterplot of SARS-CoV2 viral titer and cell type compositions of total PBMCs of T4, T8, Tgd, NK, B, PB, cM, ncM, cDC, pDC, Progen cells (R = Pearson correlation). *** p < 0.001, ** p < 0.01, * p < 0.05, ns = not significant.

Figure S2






Figure S2: Feature abundance changes of leukocyte subsets in critical COVID19. a) Heatmap of 38 surface proteins differentially expressed at day 0 ($FDR < 0.05$, $|\log(\text{fold change})| > 0$) in at least one of the 11 cell types. CD4+ T cells (T4), CD8+ T cells (T8), natural killer cells (NK), B cells (B), plasmablasts (PB), classical monocytes (cM), non-classical monocytes (ncM), and conventional dendritic cells (cDC) are shown. Each row represents a surface protein and each column is the average expression of the proteins in a particular sample across all cells of a specific type. Samples are grouped by case-control status and C19+ severity. Expression levels are row standardized. **b)** Type I-specific ISG score (y-axis) at day 0 across 8 cell types separated by case-control status and disease severity. **c)** Type II-specific ISG score (y-axis) at day 0 across 8 cell types separated by case-control status and disease severity. Boxplots show median, 25th and 75th percentile.

Figure S3


a.



b.



c.



d.




Figure S3: Surface protein abundance changes of leukocyte subsets in critical COVID19. **a)** Density plot of Pearson R correlations between normalized protein expression and corresponding transcript expression for each cell type in each sample. Correlations for 15 lineage markers highlighted in orange. **b)** Volcano plot of log fold change between C19+ and healthy controls (x-axis) versus $-\log_{10}(\text{P-value})$ (y-axis) for 10 additional cell types. Proteins that are statistically significant ($\text{FDR} < 0.05$) and have a $\log_2(\text{fold change}) > 0.5$ are highlighted. **c)** Normalized LAIR-1 surface expression (y-axis) for each cell type over the course of disease for healthy controls, C19- controls, and C19+ cases. C19+ cases are separated by disease severity and the presence of anti-IFN- $\alpha 2$ antibodies. **d)** Scatterplot of normalized LAIR-1 expression (y-axis) versus the type I-specific ISG score (x-axis) for additional cell types, showing C19+ cases colored by severity and anti-IFN- $\alpha 2$ status.